Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation

Rosenberg, Michael J.; Waugh, Michael S.; Meehan, Thomas E.

doi:10.1016/0010-7824(95)00074-k

Cited by 285 publications

(105 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Este último parámetro es muy importante, pues un método anticonceptivo demanda un período más o menos prolongado de uso, siendo la adhesión normalmente condicionada, entre otros factores, por la mayor facilidad de continuidad proporcionada. Rosenberg (21), refiere que el riesgo de abandono de la usuaria que presenta náuseas o sangrado inesperado es dos veces mayor que aquélla que no refiere uno de los síntomas.…”

Section: Tabla I Distribución Absoluta Y Proporcional De Los Motivos unclassified

Factores Asociados Al Abandono De La Anticoncepción Hormonal Oral: Un Estudio Con Los Adolescentes De La Ciudad De Rio De Janeiro

Pereira

Taquette

2007

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

RESUMENAntecedentes: El anticonceptivo hormonal oral es el método más usado por las adolescentes. Objetivo: Teniendo como objetivo contribuir con la reducción de las tasas de embarazos no previstos y sus riesgos médicos y sociales, estudiamos los factores que llevan al abandono de esta técnica. Método: Estudio experimental no controlado, con el uso de anticonceptivo oral, por seis meses, en adolescentes de 15 a 19 años, que concurren al Hospital Geral de Bonsucesso (Rio de Janeiro, Brasil) desde noviembre de 2004 a agosto de 2005. Las participantes fueron entrevistadas y se sometieron a los exámenes clínicos y de laboratorio, antes y después del uso de la medicación. Resultados: En el análisis de los datos fue utilizada la prueba Chi cuadrado con nivel de significación menor al 5%. Se constató que la edad precoz (15 a 16 años), la baja escolaridad y la relación conflictiva de la adolescente con la familia, son factores que están significativamente asociados a la no adhesión al método. Conclusiones: Para reducir la ocurrencia de embarazos no planeados son necesarios programas de salud reproductiva para adolescentes que incluyan la participación de sus familias, e inversiones que proporcionen el acceso universal y la valorización de la educación.PALABRAS CLAVES: Adolescencia, anticoncepción, abandono, embarazo en la adolescencia SUMMARY Background: The oral hormonal contraceptive is the most adopted method among adolescents. Objective: Seeking to reduce the rates of undesired pregnancy and all the medical and social risks, we studied the causing factors of the abandonment of this method. Methods: A non-controlled experimental study of the use of oral contraceptive was accomplished, for six months, with adolescents from 15 to 19 years old attended in the Hospital Geral de Bonsucesso (Rio de Janeiro, Brazil) between November 2004 and August 20005. The participants were interviewed and submitted to clinical and laboratorial tests before and after using the medication. In the data analysis the chi-square test was used with 5% level of significance. Results: It was verified that the precocious age (of 15 to 16 years old), the low education and the adolescent's conflicting relationship with their family are significant factors to the non-adhesion to the contraceptive method in question. Conclusions: We concluded that in order to reduce the occurrence of undesired pregnancies it will be necessary the adoption of programs of reproductive health for adolescents which include the participation of their families, as well as investments to provide the universal access and the valorization of the education.

show abstract

Section: Tabla I Distribución Absoluta Y Proporcional De Los Motivos unclassified

Factores Asociados Al Abandono De La Anticoncepción Hormonal Oral: Un Estudio Con Los Adolescentes De La Ciudad De Rio De Janeiro

Pereira

Taquette

2007

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

show abstract

“…20 These failures are often due to a lack of correct and consistent pill taking. [21][22][23] Thus, a combination hormonal contraceptive method with greater simplicity, such as Ortho Evra™, may help to reduce unintended pregnancies while maintaining the same noncontraceptive health benefits of estrogen and progestin. 24 In conclusion, mean serum concentrations of NGMN from the contraceptive patch, Ortho Evra™, were unchanged during all conditions in this trial.…”

Section: Norelgestromin and Ethinyl Estradiolmentioning

confidence: 99%

Pharmacokinetics of Norelgestromin and Ethinyl Estradiol Delivered by a Contraceptive Patch (Ortho Evra™/Evra™) under Conditions of Heat, Humidity, and Exercise

Abrams

Skee

Natarajan

et al. 2001

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The objectives of this randomized, open‐label, three‐period, incomplete block design study were to evaluate the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE) delivered by the contraceptive patch, Ortho EvraTM/EvraTM, and to evaluate patch adhesion under conditions of heat, humidity, and exercise. During each treatment period, 30 healthy women wore Ortho EvraTM on the abdomen for 7 days under one of six conditions (normal activity, sauna, whirlpool, treadmill, cool water immersion, ora combination of activities). Blood samples were collected before and several times to 240 hours after patch application. Mean serum concentrations of NGMN and EE generally remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, duringthe 7‐day wear period for all activities. Only 1 (1.1%) of 87 patches completely detached spontaneously. Peel force measurements were comparable for all activities. Ortho EvraTM was well tolerated. In conclusion, Ortho EvraTM delivers efficacious concentrations of NGMN and EE and maintains adhesive reliability through 7 days of wear even under conditions of heat, humidity, and exercise.

show abstract

“…These side effects may result in discontinuation of COCs [7,[10][11][12], and may have an adverse impact on quality of life [13].…”

Section: Introductionmentioning

confidence: 99%

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects

Zimmerman¹,

Foidart²,

Pintiaux³

et al. 2015

Contraception

View full text Add to dashboard Cite

Source of fundingThe study was financially supported by Pantarhei Bioscience Conflict of interestYZ is an employee of Pantarhei Bioscience (PRB), the company developing the Androgen RestoredContraceptive concept for contraception. JMF has no conflict of interest in the course of this study.AP shares expertise as a lecturer, member of advisory boards, and/or consultant, with Bayer, Amgen, Gedeon Richter and Teva/Theramex, without personal gain. JMM has nothing to declare. KC has nothing to declare. BF has received fees and grant support from the following companies (in alphabetic order); Andromed, Ardana, Euroscreen, Ferring, Genovum, Merck (MSD), Merck Serono, Organon, Ovascience, Pantharei Bioscience, PregLem, Schering, Schering Plough, Serono, Uteron Pharma, Watson Pharmaceuticals and Wyeth. HCB is the CEO and a shareholder of PRB.After publication of the paper, PRB will make the clinical study report available upon request. The authors alone are responsible for the content and the writing of the paper. Clinical Trial Registration Number: ISRCTN06414473A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT AbstractObjectives: Combined oral contraceptives (COCs) decrease androgen levels, including testosterone (T), which may be associated with sexual dysfunction and mood complaints in some women. We have shown that co-administration of dehydroepiandrosterone (DHEA) to a drospirenone (DRSP) containing COC restored total T levels to baseline and free T levels by 47%. Here we describe the effects on sexual function, mood and quality of life of such an intervention. Study design:This was a randomized, double-blind, placebo-controlled study in 99 healthy COC starters. A COC containing 30 µg ethinylestradiol (EE) and 3 mg DRSP was used for 3 cycles, followed by 6 cycles of the same COC combined with 50 mg/day DHEA or placebo. There were no statistically significant differences between groups for the MSFQ and Q-LES-Q scores. DHEA co-administration resulted in an acceptable safety profile. DHEA negated the beneficial effect of the COC on acne according to the subjects' self-assessment. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPTConclusions: Co-administration with DHEA did not result in consistent improvements in sexual function, mood and quality of life indicators in women taking EE/DRSP.Retrospectively, the 50 mg dose of DHEA may be too low for this COC.Implications A well-balanced judgment of the clinical consequences of normalizing androgens during COC use may require complete normalization of free T.

show abstract

Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation

Cited by 285 publications

References 12 publications

Factores Asociados Al Abandono De La Anticoncepción Hormonal Oral: Un Estudio Con Los Adolescentes De La Ciudad De Rio De Janeiro

Factores Asociados Al Abandono De La Anticoncepción Hormonal Oral: Un Estudio Con Los Adolescentes De La Ciudad De Rio De Janeiro

Pharmacokinetics of Norelgestromin and Ethinyl Estradiol Delivered by a Contraceptive Patch (Ortho Evra™/Evra™) under Conditions of Heat, Humidity, and Exercise

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects

Contact Info

Product

Resources

About